Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

26.43
+0.58002.24%
Post-market: 26.39-0.0403-0.15%19:59 EST
Volume:60.36M
Turnover:1.59B
Market Cap:150.27B
PE:15.31
High:26.65
Open:25.82
Low:25.81
Close:25.85
52wk High:27.69
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:1.37
T/O Rate:1.06%
Dividend:1.70
Dividend Rate:6.43%
EPS(TTM):1.73
EPS(LYR):1.42
ROE:10.60%
ROA:5.19%
PB:1.62
PE(LYR):18.64

Loading ...

Pantera Minerals Limited Announces Name Change Reflecting Broader Focus

TIPRANKS
·
Nov 27

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

TIPRANKS
·
Nov 26

Valneva Se - Pfizer Aims to Submit a Biologics License Application to U.S. FDA and Marketing Authorization Application (Maa) to European Medicines Agency in 2026

THOMSON REUTERS
·
Nov 26

Patent Challenges Cloud Hithium's IPO Prospects as Legal and Financial Risks Mount

Deep News
·
Nov 26

Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook?

Simply Wall St.
·
Nov 25

NYSE Most Active Issues

Dow Jones
·
Nov 25

Pfizer Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 24

Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating

MT Newswires Live
·
Nov 24

A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer

Simply Wall St.
·
Nov 23

First-Ever Human H5N5 Case Turns Fatal In Washington State

Benzinga
·
Nov 23

Pfizer Completes $5 Billion Public Offering

TIPRANKS
·
Nov 22

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Nov 22

Pfizer Raises $6 Billion in Multi-Tranche Note Offering

Reuters
·
Nov 22

Why Are Shares of Pfizer Up Today?

Benzinga_recent_news
·
Nov 22

FDA Approves Pfizer and Astellas' PADCEV Plus Keytruda for Bladder Cancer

Reuters
·
Nov 22

U.S. FDA Approves Padcev® Plus Keytruda® for Certain Patients With Bladder Cancer

THOMSON REUTERS
·
Nov 22

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Benzinga_recent_news
·
Nov 21

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

LiveWire
·
Nov 21

Does Recent Pipeline Progress Signal Opportunity for Pfizer Investors in 2025?

Simply Wall St.
·
Nov 20

HK Stock Movement | HBM Holdings-B (02142) Rises Over 6% in Early Trading as Subsidiary Nona Biotechnology Signs Non-Exclusive License Agreement with Pfizer

Stock News
·
Nov 20